Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at $35 per month.  The Novo Nordisk settlement reached on Jan. 27 ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

Danish pharmaceutical company Novo Nordisk has expanded its presence in Thailand by reopening its renovated and enlarged ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.